NCT03111966

Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 130 (actual)
• Sponsor: Hepa C · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicentre, descriptive, observational and ambispective study carried out in patients who are treated with Elbasvir/Grazoprevir in hospitals that included their data in Hepa-C Registry (directed by the Spanish Association for the Study of the Liver and the Networked Biomedical Research Centre for Hepatic and Digestive Diseases).

Detailed description

This is a multicentre, descriptive, observational and ambispective study carried out in patients who are treated with Elbasvir/Grazoprevir in hospitals that included their data in Hepa-C Registry (directed by the Spanish Association for the Study of the Liver and the Networked Biomedical Research Centre for Hepatic and Digestive Diseases)

Conditions

• Hepatitis C

Interventions

Type	Name	Description
OTHER	Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir	Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir

Timeline

• Start date: 2017-03-31
• Primary completion: 2017-04-30
• Completion: 2017-11-30
• First posted: 2017-04-13
• Last updated: 2019-02-11

Locations

1 site across 1 country: Spain

Regulatory

• FDA-regulated drug study